ReviewToxicology reports2020
Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy.
Review in Toxicology reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 31 citations in OpenAlex.
- Flopropione, a Cysteine Conjugate β-Lyase 1 Inhibitor, for Prevention of Cisplatin-Induced Nephrotoxicity: Protocol for a Randomized, Open-Label, Proof-of-Concept Phase 1 and 2a Trial.JMIR research protocols · 2026Article
- The Kidney in the Shadow of Cirrhosis: A Critical Review of Renal Failure.Biomedicines · 2025Review
- Biomarkers for Early Detection of Cisplatin-Induced Nephrotoxicity.Life (Basel, Switzerland) · 2025Article
- Biomarkers in Contrast-Induced Acute Kidney Injury: Towards A New Perspective.International journal of molecular sciences · 2024Review
- Cisplatin Toxicity Causes Neutrophil-Mediated Inflammation in Zebrafish Larvae.International journal of molecular sciences · 2024Article
- A Pharmacokinetic/Toxicodynamic Model of Cisplatin Nephrotoxicity Using the Kidney Injury Molecule-1 Biomarker.Journal of pharmacology & clinical toxicology · 2024Article
- The Nephroprotective Activity ofJournal of experimental pharmacology · 2024Article
- TFF3 as a Diagnostic Biomarker in Kidney Transplant Patients.International journal of molecular sciences · 2023Article
- Regulation of renal calbindin expression during cisplatin-induced kidney injury.Journal of biochemical and molecular toxicology · 2022Article
- Urine Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 to Detect Pediatric Cisplatin-Associated Acute Kidney Injury.Kidney360 · 2022Article
- "3D, human renal proximal tubule (RPTEC-TERT1) organoids 'tubuloids' for translatable evaluation of nephrotoxins in high-throughput".PloS one · 2022Article
- Urinary Exosomes Identify Inflammatory Pathways in Vancomycin Associated Acute Kidney Injury.International journal of molecular sciences · 2021Article
- Age-related changes in haematological parameters and biochemical markers of healing in the stomach of rats with acetic acid induced injury.Toxicology reports · 2020Article
- Assessment of the toxicity and biochemical effects of detergent processed cassava on renal function of Wistar rats.Toxicology reports · 2020Article
- Identification of Novel Biomarkers for Predicting Kidney Injury Due to Drugs Using "Omic" Strategies.Pharmacogenomics and personalized medicine · 2020Review
- Discrepant changes of urinary cystatin C and other urinary biomarkers in preterm neonates.Jornal de pediatriaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Proteins secreted into urine following tubular injury are being increasingly used as biomarkers of clinical and subclinical nephrotoxicity. In the present study, we sought to characterize the time-dependent urinary excretion of three promising biomarkers, kidney injury molecule-1 (KIM-1), calbindin, and trefoil factor 3 (TFF3), during two different chemotherapy cycles in 27 patients with solid tumors prescribed the anticancer drug cisplatin (≥25 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.